AU2004315197B2 - Identification of novel IgE epitopes - Google Patents

Identification of novel IgE epitopes Download PDF

Info

Publication number
AU2004315197B2
AU2004315197B2 AU2004315197A AU2004315197A AU2004315197B2 AU 2004315197 B2 AU2004315197 B2 AU 2004315197B2 AU 2004315197 A AU2004315197 A AU 2004315197A AU 2004315197 A AU2004315197 A AU 2004315197A AU 2004315197 B2 AU2004315197 B2 AU 2004315197B2
Authority
AU
Australia
Prior art keywords
antibody
ige
antibodies
cells
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2004315197A
Other languages
English (en)
Other versions
AU2004315197A1 (en
Inventor
Sek Chung Michael Fung
Danyang Huang
Sanjaya Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/002892 external-priority patent/WO2004070010A2/en
Application filed by Tanox Inc filed Critical Tanox Inc
Priority to AU2004315197A priority Critical patent/AU2004315197B2/en
Publication of AU2004315197A1 publication Critical patent/AU2004315197A1/en
Application granted granted Critical
Publication of AU2004315197B2 publication Critical patent/AU2004315197B2/en
Priority to AU2009202408A priority patent/AU2009202408A1/en
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004315197A 2004-02-02 2004-07-29 Identification of novel IgE epitopes Active AU2004315197B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2004315197A AU2004315197B2 (en) 2004-02-02 2004-07-29 Identification of novel IgE epitopes
AU2009202408A AU2009202408A1 (en) 2004-02-02 2009-06-16 Identification of novel IgE epitopes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPCT/US2004/002892 2004-02-02
PCT/US2004/002892 WO2004070010A2 (en) 2003-02-01 2004-02-02 A method for generating high affinity antibodies
PCT/US2004/002894 WO2004070011A2 (en) 2003-02-01 2004-02-02 HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
AUPCT/US2004/002894 2004-02-02
AU2004315197A AU2004315197B2 (en) 2004-02-02 2004-07-29 Identification of novel IgE epitopes
PCT/US2004/024360 WO2005075504A1 (en) 2004-02-02 2004-07-29 IDENTIFICATION OF NOVEL IgE EPITOPES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009202408A Division AU2009202408A1 (en) 2004-02-02 2009-06-16 Identification of novel IgE epitopes

Publications (2)

Publication Number Publication Date
AU2004315197A1 AU2004315197A1 (en) 2005-08-18
AU2004315197B2 true AU2004315197B2 (en) 2009-06-04

Family

ID=34841291

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004315197A Active AU2004315197B2 (en) 2004-02-02 2004-07-29 Identification of novel IgE epitopes
AU2009202408A Abandoned AU2009202408A1 (en) 2004-02-02 2009-06-16 Identification of novel IgE epitopes

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009202408A Abandoned AU2009202408A1 (en) 2004-02-02 2009-06-16 Identification of novel IgE epitopes

Country Status (8)

Country Link
EP (1) EP1718669A4 (zh)
JP (1) JP2008507474A (zh)
KR (4) KR101562114B1 (zh)
CN (1) CN102702359A (zh)
AU (2) AU2004315197B2 (zh)
CA (1) CA2552999A1 (zh)
SG (2) SG183683A1 (zh)
WO (1) WO2005075504A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241069A1 (en) * 2006-08-04 2008-10-02 Yvonne Paterson Methods and compositions for treating IgE-mediated diseases
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP2121762A1 (en) * 2007-02-15 2009-11-25 AstraZeneca AB BINDING MEMBERS FOR IgE MOLECULES
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
JP2011507816A (ja) * 2007-12-21 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
KR101644221B1 (ko) 2008-12-09 2016-07-29 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
JP7128191B2 (ja) 2017-01-06 2022-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 治療抗ＩｇＥ抗体並びにその方法及び組成物
EP3773904A1 (en) * 2018-03-26 2021-02-17 Novartis AG Methods of treating chronic spontaneous urticaria using ligelizumab
CA3220757A1 (en) 2021-06-14 2022-12-22 Novartis Ag Pharmaceutical formulation containing an anti-ige antibody

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
EP0957111A2 (en) * 1998-04-09 1999-11-17 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
WO2000023477A2 (en) * 1998-10-20 2000-04-27 University Of Sheffield Immunoglobulin variants
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO2000074716A2 (en) * 1999-06-08 2000-12-14 Smithkline Beecham Biologicals S.A. Ige peptides for allergy immunotherapy
WO2002016409A2 (en) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
WO2002034288A2 (en) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccine for treating allergy
EP1262491A2 (en) * 2001-05-22 2002-12-04 Pfizer Products Inc. Non-anaphylactogenic IgE vaccines
WO2003092714A2 (en) * 2002-04-30 2003-11-13 Glaxosmithkline Biologicals S.A. Peptide variants of ige constrained by beta-lactam bond

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69333484T2 (de) * 1992-09-24 2005-03-24 Novartis Ag Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
CN1829806A (zh) * 2003-02-01 2006-09-06 唐纳士公司 产生高亲和力抗体的方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263655A2 (en) * 1986-10-03 1988-04-13 Dainippon Pharmaceutical Co., Ltd. Novel peptides having antiallergic activity
EP0957111A2 (en) * 1998-04-09 1999-11-17 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
WO2000023477A2 (en) * 1998-10-20 2000-04-27 University Of Sheffield Immunoglobulin variants
WO2000050461A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
WO2000074716A2 (en) * 1999-06-08 2000-12-14 Smithkline Beecham Biologicals S.A. Ige peptides for allergy immunotherapy
WO2002016409A2 (en) * 2000-08-22 2002-02-28 Glaxosmithkline Biologicals S.A. Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
EP1195161A2 (en) * 2000-08-30 2002-04-10 Pfizer Products Inc. Anti-IgE vaccines
WO2002034288A2 (en) * 2000-10-27 2002-05-02 Smithkline Beecham Biologicals S.A. Vaccine for treating allergy
EP1262491A2 (en) * 2001-05-22 2002-12-04 Pfizer Products Inc. Non-anaphylactogenic IgE vaccines
WO2003092714A2 (en) * 2002-04-30 2003-11-13 Glaxosmithkline Biologicals S.A. Peptide variants of ige constrained by beta-lactam bond

Also Published As

Publication number Publication date
KR20120056297A (ko) 2012-06-01
KR101581659B1 (ko) 2015-12-31
SG149892A1 (en) 2009-02-27
CN102702359A (zh) 2012-10-03
KR101562114B1 (ko) 2015-11-20
KR20140021058A (ko) 2014-02-19
KR20070008578A (ko) 2007-01-17
AU2009202408A1 (en) 2009-07-09
AU2004315197A1 (en) 2005-08-18
JP2008507474A (ja) 2008-03-13
KR101365375B1 (ko) 2014-02-19
EP1718669A4 (en) 2007-10-10
CA2552999A1 (en) 2005-08-18
EP1718669A1 (en) 2006-11-08
SG183683A1 (en) 2012-09-27
WO2005075504A1 (en) 2005-08-18
KR20130088198A (ko) 2013-08-07

Similar Documents

Publication Publication Date Title
AU2004209638B2 (en) High affinity anti-human IgE antibodies
AU2009202408A1 (en) Identification of novel IgE epitopes
US20110200604A1 (en) IDENTIFICATION OF NOVEL IgE EPITOPES
AU2012261739A1 (en) Identification of novel IgE epitopes
AU2013263817A1 (en) High affinity anti-human IgE antibodies
MXPA06008690A (es) Identificacion de epitopos ige novedosos

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)